Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Conduit Pharmaceuticals ( (CDT) ) is now available.
On May 15, 2025, Conduit Pharmaceuticals Inc. announced a 1-for-15 reverse stock split of its common stock, which was approved by stockholders on May 5, 2025. The reverse stock split will take effect on May 19, 2025, and the stock will begin trading on a split-adjusted basis on Nasdaq on May 20, 2025, under the ticker symbol ‘CDT’. This move is expected to consolidate the company’s shares, potentially impacting its stock price and market positioning.
More about Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc. is a dynamic, multi-asset clinical stage life science company focused on delivering an efficient model for compound development. The company acquires and funds the development of Phase 2-ready assets, utilizing an integrated platform driven by artificial intelligence and cybernetics, and aims for exits through third-party license deals following successful clinical trials.
Average Trading Volume: 3,081,343
Technical Sentiment Signal: Sell
Current Market Cap: $4.54M
Find detailed analytics on CDT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue